Central Institute of Mental Health, Department of Psychiatry,
Mannheim, Baden-Wurttemberg, 68159, Germany
NCT Number: NCT00224315
We aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 4
Mannheim, Baden-Wurttemberg, 68159, Germany
Partial response of schizophrenic psychoses to a monotherapy with clozapine is a frequent problem of clinical psychiatry. Current problems are treatment resistant positive and/or negative symptoms, as well as side effects. Therefore, different strategies of augmentations have been applied. Based on successful experiences in case reports and results of other work groups, we aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Central Institute of Mental Health, Mannheim
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06319170
Mental Disorders, Psychotic Disorders
Los Alamitos, California, United States
View Trial DetailsNCT04512066
Mental Disorders, Psychotic Disorders
Little Rock, Arkansas, United States
View Trial DetailsNCT02192593
Mental Disorders, Psychotic Disorders
Cambridge, Massachusetts, United States
View Trial DetailsNCT02808533
Mental Disorders, Psychotic Disorders
Toronto, Ontario, Canada
View Trial Details